13 Things to Know About Medication During Pregnancy — From a Medical Perspective

The Food and Drug Administration's pregnancy category system, which classified medications from Category A through X, served as the primary framework for medication safety assessment during pregnancy for decades until its replacement in 2015 with the Pregnancy and Lactation Labeling Rule (PLLR). This evolution represents a fundamental shift from simplistic letter categories to comprehensive, narrative-based risk assessments that provide healthcare providers with detailed information about available data, potential risks, and clinical considerations. The new labeling system requires manufacturers to include three distinct sections: pregnancy (including labor and delivery), lactation, and females and males of reproductive potential. This approach acknowledges that pregnancy medication decisions cannot be reduced to simple categorical assignments but require nuanced understanding of timing, dosage, duration of exposure, and individual patient factors. The modern framework emphasizes the importance of discussing both the risks of taking medications and the risks of untreated conditions during pregnancy, recognizing that maternal health directly impacts fetal wellbeing. Healthcare providers now have access to more detailed information about animal studies, human data when available, and specific recommendations for monitoring and management. This comprehensive approach enables more informed shared decision-making between patients and providers, moving away from blanket restrictions toward individualized risk-benefit assessments that consider the unique circumstances of each pregnancy.

2. Physiological Changes That Affect Drug Metabolism During Pregnancy

Pregnancy induces profound physiological changes that significantly alter drug absorption, distribution, metabolism, and elimination, fundamentally changing how medications behave in the maternal system and their potential impact on the developing fetus. Cardiovascular adaptations include increased cardiac output, expanded blood volume, and altered protein binding, which can affect drug distribution and concentration at target sites. The gastrointestinal system experiences delayed gastric emptying and altered pH levels, potentially affecting oral medication absorption rates and bioavailability. Renal function undergoes substantial changes with increased glomerular filtration rate and renal blood flow, leading to enhanced clearance of many medications and potentially requiring dosage adjustments to maintain therapeutic efficacy. Hepatic metabolism is particularly complex during pregnancy, with some cytochrome P450 enzymes showing increased activity while others are inhibited, creating drug-specific patterns of metabolic changes that can vary throughout pregnancy. These alterations mean that standard non-pregnant dosing regimens may result in subtherapeutic or potentially toxic levels during pregnancy. Additionally, the expanding maternal blood volume and increased total body water can dilute drug concentrations, while decreased albumin levels may increase the free fraction of highly protein-bound medications. Understanding these physiological adaptations is crucial for healthcare providers to optimize medication dosing, timing, and monitoring strategies throughout pregnancy, ensuring both maternal therapeutic benefit and fetal safety.

3. Critical Periods of Fetal Development and Medication Sensitivity

The timing of medication exposure during pregnancy is paramount, as different stages of fetal development present varying degrees of vulnerability to pharmaceutical interventions. The first trimester, particularly the period from 3-8 weeks post-conception, represents the most critical window for teratogenic effects as this encompasses organogenesis when major organ systems are forming. During this embryonic period, exposure to certain medications can result in structural malformations, making careful medication selection and timing essential for preventing birth defects. The second trimester is generally considered the safest period for medication use, as major organ formation is complete, though functional development continues and some medications can still affect growth and development. The third trimester presents unique considerations as medication exposure can affect fetal growth, organ maturation, and preparation for extrauterine life, with particular attention needed for medications that might affect labor, delivery, or neonatal adaptation. Certain drug classes demonstrate period-specific risks: ACE inhibitors are particularly dangerous in the second and third trimesters due to effects on fetal kidney development, while some antiepileptic drugs pose the highest teratogenic risk during early organogenesis. Understanding these temporal vulnerabilities allows healthcare providers to time medication initiation, modification, or discontinuation to minimize fetal risk while maintaining maternal health. The concept of critical periods also extends to medication withdrawal, as abrupt discontinuation of certain medications can pose risks that outweigh the benefits of avoidance, necessitating careful tapering schedules and alternative treatment strategies.

4. Essential Medications That Should Never Be Stopped During Pregnancy

Certain medical conditions require continuous medication management throughout pregnancy, where the risks of treatment discontinuation far exceed the potential risks of continued medication use, making these drugs essential for maternal and fetal wellbeing. Antiepileptic drugs represent a prime example, as uncontrolled seizures during pregnancy pose significant risks including maternal injury, placental abruption, fetal hypoxia, and increased risk of sudden unexpected death in epilepsy (SUDEP). While some antiepileptic medications carry teratogenic risks, the benefits of seizure control typically outweigh these concerns, though medication selection and dosing may require adjustment under specialist supervision. Insulin and other diabetes medications are crucial for maintaining glycemic control, as uncontrolled diabetes significantly increases risks of congenital malformations, macrosomia, preeclampsia, and perinatal complications. Thyroid medications, particularly levothyroxine for hypothyroidism, are essential as untreated thyroid dysfunction can severely impact fetal brain development and increase risks of pregnancy complications. Certain psychiatric medications, including some antidepressants and mood stabilizers, may need to be continued when the risk of maternal mental health deterioration poses significant threats to both mother and fetus. Cardiac medications for serious arrhythmias or heart failure often require continuation with careful monitoring and potential dosage adjustments. Asthma medications, particularly inhaled corticosteroids and bronchodilators, are generally continued as uncontrolled asthma poses greater risks than medication exposure. The key principle underlying these decisions is that maternal health directly impacts fetal health, and severe maternal illness or death represents the greatest threat to fetal wellbeing, making continued treatment with appropriate monitoring the preferred approach.

5. Common Over-the-Counter Medications and Their Pregnancy Safety Profiles

Over-the-counter medications present unique challenges during pregnancy as they are readily accessible without prescription oversight, yet many carry important considerations for maternal and fetal safety that require careful evaluation. Acetaminophen (paracetamol) is widely considered the safest analgesic and antipyretic option during pregnancy, with extensive use data supporting its safety when used at recommended doses, though recent research has raised questions about potential associations with neurodevelopmental outcomes that warrant further investigation. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen present timing-specific risks, being generally avoided in the first trimester due to potential cardiovascular malformation risks and contraindicated in the third trimester due to effects on fetal ductus arteriosus closure and oligohydramnios. Aspirin requires special consideration, as low-dose aspirin (81mg) is actually recommended for certain high-risk pregnancies to prevent preeclampsia, while higher doses carry bleeding risks and should be avoided near delivery. Antihistamines show variable safety profiles, with first-generation antihistamines like chlorpheniramine and diphenhydramine having more safety data than newer formulations, though loratadine and cetirizine are increasingly considered acceptable options. Decongestants, particularly pseudoephedrine and phenylephrine, raise concerns about vasoconstriction and potential effects on placental blood flow, making non-pharmacological approaches preferable for nasal congestion. Antacids and acid reducers generally show good safety profiles, with calcium carbonate and magnesium-based antacids being preferred over aluminum-containing formulations. The key message for pregnant women is that "over-the-counter" does not mean "automatically safe during pregnancy," and consultation with healthcare providers before using any OTC medications ensures appropriate risk-benefit assessment and optimal maternal-fetal outcomes.

6. Prescription Medications Requiring Special Monitoring and Dose Adjustments

Many prescription medications require enhanced monitoring and dosage modifications during pregnancy due to the physiological changes that affect drug pharmacokinetics and the need to optimize maternal treatment while minimizing fetal exposure. Antiepileptic drugs exemplify this complexity, as pregnancy can alter drug clearance significantly, potentially leading to breakthrough seizures if levels drop too low, while maintaining the lowest effective dose minimizes teratogenic risks. Lamotrigine clearance can increase by 200-300% during pregnancy, necessitating frequent level monitoring and dose adjustments, with careful planning for postpartum dose reduction to prevent toxicity. Thyroid medications require close monitoring as thyroid hormone requirements typically increase during pregnancy, with TSH levels checked every 4-6 weeks and levothyroxine doses adjusted accordingly to prevent maternal hypothyroidism and its associated fetal complications. Insulin requirements in diabetic patients often change dramatically throughout pregnancy, with increased insulin resistance in the second and third trimesters requiring frequent glucose monitoring and dose adjustments to maintain optimal glycemic control. Warfarin presents particular challenges as it crosses the placenta and carries teratogenic risks, often necessitating conversion to heparin or low molecular weight heparin with careful monitoring of anticoagulation parameters. Lithium requires specialized monitoring due to changes in renal clearance during pregnancy and increased risks of cardiac malformations with first-trimester exposure, often requiring dose adjustments and enhanced cardiac monitoring. Immunosuppressive medications used in organ transplant recipients or autoimmune conditions require careful balance between preventing rejection or disease flares while minimizing fetal exposure, often involving multidisciplinary care teams. The principle underlying all these adjustments is that pregnancy is not a time to simply continue pre-pregnancy regimens unchanged, but rather requires proactive monitoring and adjustment to ensure optimal outcomes for both mother and fetus.

7. Teratogenic Medications and Absolute Contraindications

Certain medications carry such significant teratogenic risks that they are absolutely contraindicated during pregnancy, requiring immediate discontinuation upon pregnancy recognition and implementation of highly effective contraception for women of reproductive age taking these medications. Isotretinoin (Accutane) represents one of the most potent human teratogens, causing severe craniofacial, cardiac, and central nervous system malformations in 25-35% of exposed pregnancies, necessitating the iPLEDGE program that requires multiple forms of contraception and monthly pregnancy testing. Thalidomide, historically infamous for causing phocomelia, remains in use for certain cancers and inflammatory conditions but requires strict pregnancy prevention programs due to its devastating teratogenic effects. Methotrexate, widely used for autoimmune conditions and certain cancers, is a folate antagonist that causes multiple congenital anomalies and is absolutely contraindicated in pregnancy, requiring folate supplementation even in non-pregnant women to reduce toxicity. Warfarin crosses the placenta freely and causes warfarin embryopathy, characterized by nasal hypoplasia, stippled epiphyses, and central nervous system abnormalities, particularly with first-trimester exposure. ACE inhibitors and angiotensin receptor blockers (ARBs) cause severe fetal kidney damage, oligohydramnios, and growth restriction, particularly with second and third-trimester exposure, making them contraindicated throughout pregnancy. Valproic acid carries the highest teratogenic risk among antiepileptic drugs, causing neural tube defects, facial dysmorphism, and cognitive impairment, requiring careful consideration of alternatives in women of reproductive age. Certain chemotherapy agents, particularly alkylating agents and antimetabolites, carry high risks of fetal death and malformations, necessitating pregnancy avoidance and careful timing of conception after treatment completion. The management of patients taking these medications requires proactive counseling about pregnancy risks, implementation of effective contraception, and development of alternative treatment strategies for women planning pregnancy.

8. Mental Health Medications and the Risk-Benefit Balance

Mental health medications during pregnancy present particularly complex risk-benefit considerations, as untreated maternal psychiatric conditions can have profound effects on both maternal and fetal wellbeing, while medication exposure carries potential risks that must be carefully weighed against these consequences. Selective serotonin reuptake inhibitors (SSRIs) represent the most commonly prescribed antidepressants during pregnancy, with sertraline and citalopram generally considered first-line options due to extensive safety data, though paroxetine is avoided due to increased cardiac malformation risks. The decision to continue antidepressant therapy during pregnancy must consider the severity of maternal depression, history of previous episodes, response to non-pharmacological interventions, and the significant risks of untreated depression including poor prenatal care, substance abuse, preterm delivery, and postpartum depression. Third-trimester SSRI exposure has been associated with transient neonatal adaptation syndrome, characterized by jitteriness, poor feeding, and respiratory distress, but these symptoms are typically mild and self-limiting. Mood stabilizers present unique challenges, with lithium carrying first-trimester cardiac risks (Ebstein's anomaly) but potentially being the safest option for severe bipolar disorder when benefits outweigh risks, requiring specialized monitoring including fetal echocardiography. Antipsychotic medications show variable safety profiles, with older agents like haloperidol having more safety data than newer atypical antipsychotics, though quetiapine and olanzapine are increasingly used when treatment is necessary. Benzodiazepines are generally avoided due to potential teratogenic effects and neonatal withdrawal syndrome, though short-term use may be necessary for severe anxiety or panic disorders. The key principle in managing mental health during pregnancy is that maternal mental health directly impacts fetal development and pregnancy outcomes, making treatment decisions highly individualized and requiring close collaboration between obstetricians, psychiatrists, and patients to optimize outcomes for both mother and child.

9. Antibiotics and Infection Management During Pregnancy

Antibiotic selection during pregnancy requires careful consideration of both maternal infection treatment needs and fetal safety, as untreated infections can pose significant risks to pregnancy outcomes while certain antibiotics carry specific contraindications or concerns. Penicillins and cephalosporins are generally considered first-line antibiotics during pregnancy due to extensive safety data and lack of teratogenic effects, making them preferred choices for common infections including urinary tract infections, respiratory tract infections, and group B streptococcus prophylaxis. Macrolides, particularly erythromycin and azithromycin, are generally safe alternatives for patients with penicillin allergies, though clarithromycin has raised some concerns about cardiovascular malformations and is typically avoided. Clindamycin is considered safe and effective for anaerobic infections and as an alternative for group B streptococcus prophylaxis in penicillin-allergic patients. However, several antibiotic classes are contraindicated during pregnancy due to specific fetal risks: tetracyclines cause tooth discoloration and bone growth inhibition, fluoroquinolones may affect cartilage development, and aminoglycosides carry risks of eighth cranial nerve damage and nephrotoxicity. Sulfonamides are generally avoided near term due to risks of kernicterus from bilirubin displacement. Nitrofurantoin is commonly used for urinary tract infections but is avoided near term due to potential hemolytic anemia in glucose-6-phosphate dehydrogenase-deficient newborns. The management of specific infections during pregnancy often requires specialized considerations: urinary tract infections require prompt treatment to prevent pyelonephritis and preterm labor, while bacterial vaginosis treatment may help reduce preterm birth risks. The principle guiding antibiotic use in pregnancy is that untreated bacterial infections pose greater risks to maternal and fetal health than appropriate antibiotic therapy, making prompt, appropriate treatment essential while avoiding unnecessary or prolonged antibiotic exposure.

10. Pain Management Strategies and Analgesic Safety

Pain management during pregnancy requires a multifaceted approach that balances effective maternal symptom relief with fetal safety considerations, incorporating both pharmacological and non-pharmacological interventions tailored to the specific type and severity of pain. Acetaminophen remains the first-line analgesic for mild to moderate pain during pregnancy, with extensive safety data supporting its use at recommended doses throughout all trimesters, though recent studies suggesting potential associations with neurodevelopmental outcomes warrant continued research and judicious use. Nonsteroidal anti-inflammatory drugs (NSAIDs) present timing-specific considerations, with ibuprofen and naproxen generally avoided in the first trimester due to potential cardiovascular malformation risks and contraindicated after 30 weeks gestation due to effects on fetal ductus arteriosus closure, decreased amniotic fluid, and potential complications during labor and delivery. Topical analgesics and anti-inflammatory preparations may offer localized relief with minimal systemic absorption, though even topical preparations require consideration of their active ingredients and potential for systemic effects. Opioid medications present complex considerations during pregnancy, as while they may be necessary for severe pain conditions, they carry risks of neonatal abstinence syndrome with chronic use and require careful monitoring and tapering strategies